Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 478 participants.

Also called NCT07487103

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 478 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07487103
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07487103. Randomized; no masking; primary purpose treatment. Start 2026-05-01 (anticipated); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes
Intervention (Drug)
QLG1091
Intervention (Drug)
Rybelsus
Lead sponsor
Qilu Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07487103
Content hash
7552ad9c407e7cdf2db0d1f5fc862903f0cfbc0894bfdf944ae8db68dbb11640